NEW YORK (GenomeWeb) – Biocartis today reported a nearly 500 percent year-over-year increase in its revenues for the first half of 2015. 

For the first half of the year, the Belgian molecular diagnostics firm said that revenues reached €6.6 million ($7.4 million), up from €1.1 million in H1 2014. The uptick was driven by a €4.6 million increase in collaboration revenues resulting from a license and development deal with Janssen Pharmaceutica, and a €900,000 increase in product sales, the company said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.